ArticleViruses2025
Three Years After COVID-19 Vaccination, Anti-Spike SARS-CoV-2 Antibody Concentration Decreases and Is Accompanied by Increasing Anti-Nucleocapsid Seropositivity.
Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesThe anti-spike (S) SARS-CoV-2 antibodies confer neutralizing properties and their concentration may be related to COVID-19 protection. Anti-nucleocapsid (N) SARS-CoV-2 antibodies in mRNA COVID-19 vaccine recipients indicate infection. The aim of this study was to analyze the anti-S and anti-N titers 3 years after COVID-19 vaccination.
methodsNinety-nine vaccinated healthcare workers provided blood samples in 2024 and filled out questionnaires about their COVID-19 history and boosters acceptance. Anti-spike and anti-nucleocapsid IgG were assessed with commercially available immunoassays, DiaSorin's SARS-CoV-2 TrimericS IgG and Abbott's SARS-CoV-2 IgG, respectively.
resultsThree years after the primary COVID-19 vaccination, the anti-S SARS-CoV-2 antibody concentration was still high. However, it dropped in comparison to the data obtained a year before (3600 vs. 2040 BAU/mL), possibly due to the lack of boosters. In contrast, the percentage of anti-N seropositive individuals grew from 34% two years after vaccination to 40.4% after three years. Subjects with SARS-CoV-2 infection within a year prior to the antibody measurements had statistically significantly higher median anti-S concentrations than those with tentatively no contact with SARS-CoV-2 (2940 vs. 1930 BAU/mL).
conclusionsOverall, our data indicates that although the booster vaccinations' acceptance decreases, the circulating SARS-CoV-2 stimulates humoral immunity, resulting in high anti-S antibody concentrations even three years after the vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.